MPH works by inhibiting the presynaptic dopamine transporter [2], and the conventional, immediate release (IR) formulation of MPH became a mainstay of treatment for ADHD since 1955 when ADHD was termed Minimal Brain Dysfunction (MBD) [3]. The gene discussed is SLC6A3; the disease is attention deficit-hyperactivity disorder.